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Abstract
Objectives
To utilize phosphorescence to monitor hypoxic microenvironment in solid-tumors and inves-
tigate cancer chemotherapeutic effects in vivo.
Methods
A hypoxia-sensitive probe named BTP was used to monitor hypoxic microenvironment in
solid-tumors. The low-dose metronomic treatment with cisplatin was used in anti-angioge-
netic chemotherapeutic programs. The phosphorescence properties of BTP were detected
by a spectrofluorometer. BTP cytotoxicity utilized cell necrosis and apoptosis, which were
evaluated by trypan blue dye exclusion and Hoechst33342 plus propidium iodide assays.
Tumor-bearing mouse models of colon adenocarcinoma were used for tumor imaging in
vivo. Monitoring of the hypoxic microenvironment in tumors was performed with a Maestro 2
fluorescence imaging system. Tumor tissues in each group were harvested regularly and
treated with pathological hematoxylin and eosin and immunohistochemical staining to con-
firm imaging results.
Results
BTP did not feature obvious cytotoxicity for cells, and tumor growth in low-dose metronomic
cisplatin treated mice was significantly inhibited by chemotherapy. Hypoxic levels signifi-
cantly increased due to cisplatin, as proven by the expression level of related proteins.
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Phosphorescence intensity in the tumors of mice in the cisplatin group was stronger and
showed higher contrast than that in tumors of saline treated mice.
Conclusions
We develop a useful phosphorescence method to evaluate the chemotherapeutic effects of
cisplatin. The proposed method shows potential as a phosphorescence imaging approach
for evaluating chemotherapeutic effects in vivo, especially anti-angiogenesis.
Introduction
Tumor is an extremely common problem for human beings, and chemotherapy is still the
main treatment measure for tumor therapy. In clinical trials, the tumor size is a main and su-
perficial characteristic without monitoring of microenvironment. As investigators do not know
more if they don’t have complicated analysis, they can neither evaluate chemotherapeutic ef-
fects in perspective nor design new chemotherapy regimens to predict its effects. Therefore, a
reasonable method is urgently needed for evaluating chemotherapeutic effects. To develop
such a method, a specific landmark of tumor which is significantly different with normal tis-
sues should be indicated.
Recent studies found hypoxia is a key feature in the solid-tumor microenvironment [1], fa-
cilitates tumor progression, metastatic spread, and resistance to radiation and chemotherapy.
Hypoxia-inducible factor 1 (HIF-1) is the most significant hypoxia-related protein, and its cel-
lular signal pathway has been studied for many years [2]. HIF-1 can activate transcription of
many genes involved in angiogenesis, cell growth and survival, glucose metabolism, invasion,
metastasis, and drug resistance, to name a few [3]. Angiogenesis-related protein vascular endo-
thelial growth factor (VEGF) and multidrug resistance 1 (MDR1) are up-regulated by hypoxic
conditions in tumor cells. Angiogenesis is mostly an adaptive response to tissue hypoxia, and
also an essential requirement for neoplastic growth [4]. Hence, hypoxia and angiogenesis are
hallmarks of cancer and major targets in cancer therapy, and several target-hypoxia/angiogene-
sis agents are being actively studied for their antitumor activity in preclinical models and/or in
clinical trials [5].
The impact of chemotherapy on the tumor oxygenation environment remains controver-
sial. Early work from pioneers, such as computed tomography (CT) perfusion [6] and dy-
namic contrast-enhanced magnetic resonance imaging (MRI) [7], suggest that reduction of
newly formed blood vessels starves tumors from nutrients and oxygen, thereby reducing
tumor growth and inducing tumor cell death (starvation hypothesis). According to the Jain’s
hypothesis, treatment with bevacizumab can primarily improve chemotherapeutic efficacy
by normalizing the tumor vasculature, resulting in more effective oxygen and drug delivery
[8]. What is clear in these tumor studies is that the mechanisms of chemotherapy are fairly
complex and depend on the tumor type, hypoxia detection time point, and hypoxia modality
[9]. Various cytotoxic chemotherapeutic agents have anti-angiogenesis effects [10, 11], and
low-dose metronomic chemotherapeutic treatment with cisplatin can affect angiogenesis
[12, 13]. To date, however, intuitive and direct methods for detecting changes in tumor hyp-
oxic microenvironment resulting from chemotherapy are limited [14–16].
Several measures have been developed to observe and measure hypoxic microenviron-
ment. The most accurate method involves the use of an oxygen electrode to penetrate the
tumor tissue [17]; this method, however, is invasive and may only measure O2 in tissues
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where penetration occurs. As well, the oxygen electrode may directly consume O2. Therefore,
noninvasive approaches are necessary to monitor hypoxia in tumors both accurately and
reliably.
A number of noninvasive imaging techniques for measuring tumor hypoxia have been ex-
ploited, including radionuclide imaging (positron emission tomography [PET] and single-
photon emission computed tomography [SPECT]), MRI, and optical imaging [18]. In hypox-
ia monitoring, nitroimidazole compounds, such as fluoromisonidazole (FMISO) [19] and
fluoroazomycinarabinoside (FAZA) [20], have been developed as hypoxia-targeting PET
probes for noninvasive hypoxia monitoring. Cu (II)-ATSM is another PET probe without
nitroimidazole. These probes radiolabeled with radioisotope can be reduced by enzyme sys-
tems in hypoxic tissue, which is believed to bind to macromolecules [21–23]. Among these
imaging techniques, optical imaging has several advantages, including high sensitivity and
resolution, low imaging cost, and lack of radioisotope requirement. Phosphorescent coordi-
nation compounds show luminescent emissions that are distinct from those of the tumor
hypoxia targeting probes described above. They are distributed systemically through the
whole body and emit phosphorescence where the oxygen supply is insufficient.
Iridium (III) coordination compounds are superior to other phosphorescence-emitting
probes, such as platinum (II)- and palladium (II)-porphyrins, and ruthenium (II) coordination
compounds, because of their small size and suitable phosphorescence lifetime of the former;
these characteristics are favorable for oxygen sensing in living animals [24]. Furthermore, the
optical properties of iridium (III) coordination compounds may be tuned by adjusting ancillary
ligands [25].
An effective red phosphorescence-emitting probe BTP, [bis(2-(2’-benzothienyl)pyridinato-
N, C3’) iridium (acetylacetonate)] [25] was used in the medical field [26] and developed using
nanotechnology [27] in our earlier work. It is quiescent in normoxic tissues but become emis-
sive in hypoxic regions because of their oxygen-dependent triplet state (oxygen quenching).
This finding provides opportunities for hypoxia imaging with high contrast [26].
The purpose of the present study is to develop a phosphorescence imaging approach using
BTP to monitor hypoxic changes resulting from chemotherapeutic treatment in vivo. We hy-
pothesize that the hypoxia-sensitive probe BTP is useful for quantitatively evaluating changes
in tumor hypoxia during chemotherapy. We designed an experiment using BTP phosphores-
cence imaging to monitor tumor hypoxic microenvironment in vivo during cisplatin treatment
to assess chemotherapeutic effects and the reasonability of treatment (Fig. 1). The results of
this paper agreed with our hypothesis; this sensor showed great potential for hypoxia-targeting
cancer imaging in vitro and in vivo, and might be used as a potent biomarker for real-time
monitoring of hypoxic microenvironment and detection of overall changes resulting from che-
motherapeutic treatment. Therefore, BTP may be applied as a promising and novel phospho-
rescence imaging method for evaluating chemotherapeutic effects in vivo.
Materials and Methods
Materials
BTP synthesized according to the literature was purchased from American Dye Source, Inc.
Mouse monoclonal antibodies to HIF-1α and VEGF were purchased from Sigma-Aldrich
Trading Co., Ltd. (Shanghai, China). Other reagents were purchased from Aladdin Chemical
Reagents Co., Ltd. All reagents were of analytical grade and directly used without
further purification.
A mouse colon adenocarcinoma (CT-26) cell line [28] was purchased from the Chinese
Academy of Sciences (Shanghai). Cell culture consumables were purchased from Thermo
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Fisher Scientific Co., Ltd. (Shanghai, China). A streptavidin-biotin2 system labeled with
horseradish peroxidase (LSAB2 System-HRP) was purchased from Dako Co., Ltd. Male nude
BALB/c mice were purchased from the Department of Experimental Animals, Shanghai Med-
ical College, Fudan University. The mice were raised under a standard housing environment
until 6 weeks of age and featured body weights of at least 25.0 g. All animal experiments were
approved by the Ethics Committees of Xi'an Jiaotong University.
Phosphorescence properties of BTP
A spectrofluorometer (FluoroMax-4, HORIBA JobinYvon, France) was used to measure the
phosphorescence spectra of BTP under different conditions (hypoxia and normoxia). Briefly,
5 mg of BTP was dissolved in 35 mL of DMSO; 3 mL of this mixture was pipetted into a quartz
cuvette. Phosphorescence excitation spectroscopy was performed at an excitation wavelength
of 480 nm.
To observe the phosphorescent performance of BTP in a hypoxic atmosphere, two quartz
cuvettes with 3.0 mL of BTP were placed under a handheld UV lamp at an excitation wave-
length of 365 nm in a dark room. Photographs of the cuvettes were obtained by a camera
Fig 1. The schematic diagram of our research. (A) Chemical structure of BTP and the scheme of its effects in vivo. (B) The experimental design of BTP
optical imaging for monitoring tumor hypoxic microenvironment in vivo in the cisplatin therapy process.
doi:10.1371/journal.pone.0121293.g001
Phosphorescence Evaluate Chemotherapeutic Effects in Solid-Tumors
PLOS ONE | DOI:10.1371/journal.pone.0121293 March 18, 2015 4 / 16
(Powershot A650IS, Canon, Japan). Nitrogen was used to purge the air out from one of the
quartz cuvettes; the other tube was used as a control. In both tubes, the BTP concentration was
set to 0.14 mgmL−1.
Cytotoxicity evaluation of BTP
To evaluate the cytotoxicity of BTP, CT-26 cell necrosis and apoptosis were evaluated in cell cul-
tures to which BTP had been added for up to 72 h using trypan blue dye exclusion and Hoechst
33342 plus propidium iodide (PI) assays. BTP concentrations of 0, 1, 5, 20, 50, 100 μMwere test-
ed. Cholesterol was used as a negative control and 7-ketocholesterol [29] was used as a positive
control; both molecules feature lipophilicity similar to that of BTP [30].
Cell uptake of BTP
CT-26 cells were cultured in DMEMmedium containing 25 mmolL−1 of glucose with 10%
FBS at 37°C and then cultured under 5% or 20% O2 in a concentration-changeable multi-gas
incubator (MCO-5M, Sanyo, Japan) for 24 h at 37°C. Afterward, BTP dissolved in DMSO was
added to the medium at a final concentration of 5 μM for 2 h. An inverted fluorescence micro-
scope (Eclipse Ti-S, Nikon, Japan) with a camera was used to obtain phosphorescence images.
Nude BALB/c mice model of colon adenocarcinoma
Tumor transplants were established in male nude BALB/c mice by injection of 5×106 mouse
colon adenocarcinoma-derived CT-26 cells to the left anterior axilla. Experiments with tumor-
bearing mice were performed one week after injection of tumor cells.
Low-dose metronomic chemotherapy treatment with cisplatin
To evaluate hypoxic changes resulting from chemotherapy, all mice were treated for 21 days
with low-dose metronomic cisplatin, a well-studied anti-cancer chemotherapeutic drug com-
monly used against different human tumors. When the tumor volumes approached 60–70 mm3,
saline (100 μL) and cisplatin (1 mgkg−1, 100 μL) were intraperitoneally injected into the 12
CT-26 tumor-bearing nude mice every two days (6 with saline, 6 with cisplatin).
Monitoring tumor hypoxic microenvironment in vivo
The tumor size in each mouse was measured every three days after tumor implantation by a
caliper and calculated as follows: volume = (tumor length) × (tumor width)2/2. Every three
days, hypoxic changes in tumors in vivo were monitored by carrying out optical imaging, be-
ginning from day nine post-treatment as described above. BTP DMSO/saline solution was in-
jected intravenously into the animals 2 h before imaging. Phosphorescent images of the whole
mouse body as well as a close-up image were obtained using an in vivo fluorescence imaging
system (Maestro 2, CRI, USA) under the following conditions: “Blue” filter model; excitation
filter range, 455 nm (435–480 nm); emission filter range, 490 nm longpass; acquisition setting,
500 to 720 nm in 10 nm steps. The auto-fluorescence of mice and BTP phosphorescence were
obtained and then unmixed using Maestro spectral software.
Pathological and immunohistochemical studies
Tumors were quickly removed and fixed with 4% paraformaldehyde in 0.1 M phosphate buffer.
After fixation, tumors were immersed in a series of sucrose solutions with increasing concen-
trations for 48 h at 4°C. For the pathological study, tumor samples were embedded in Tissue-
Tek O. C. T. compound mounting medium (Sakura Finetek Inc., CA, USA), frozen in liquid
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nitrogen, and cryostat-sectioned (5 μm) by a cryostat (Jung CM3000, Leica, Germany). Histo-
logical sections from cryostat blocks were stained with hematoxylin and eosin (H&E). Tissue
antigens were retrieved after formalin-fixing and paraffin-embedding, and antigens were
stained with the primary antibodies (mouse monoclonal antibodies to HIF-1α or VEGF; 1:200
dilution). A second immune reaction was performed using LSAB2 System-HRP. The quantita-
tive data of IOD SUM were extracted using Image-Pro Plus 6 (Media Cybernetics Co., Ltd.,
USA).
Statistical analysis
Data were presented as mean ± SE. Three repetitions or sets were performed. T-test was per-
formed to determine differences among samples. A p value of less than 0.05 was considered
significant (p<0.05, p<0.01, p<0.001). The Software packages of GraphPad Prism 5
(GraphPad Software, Inc., USA) and SPSS 19.0 (IBM Co., USA) were used in the statistical
analysis.
Results
Phosphorescence properties of BTP
The chemical structure of BTP is shown in Fig. 1. BTP had a broad excitation wavelength rang-
ing from 400 to 550 nm. When excited at its maximum excitation wavelength (480 nm), BTP
showed a maximum emission peak at 612 nm, with a shoulder at 667 nm (Fig. 2A). DMSO
made the spectra shift red compared with low polarity solvent. Part of the emission curve ex-
tends to the near-infrared region (650–900 nm), which is the preferred optical window for in
vivo imaging because of the relatively low tissue absorption and auto-fluorescence in this re-
gion. BTP emits strong phosphorescence where the O2 supply is insufficient. The intensity of
emission peaks changed under different conditions (hypoxia and normoxia), and the peak in-
tensity of the compound in pure nitrogen was about 3.5 times that in the atmosphere [27].
Phosphorescent images of BTP samples under normoxic (left) and hypoxic (right) condi-
tions are shown in Fig. 2A. After pumping nitrogen through the BTP solution to generate a
hypoxic environment, the phosphorescence signals increased significantly in the test quartz cu-
vettes. The relationship between pO2 and phosphoresce intensity are shown in Fig. 2B. Accord-
ing to Stern-Volmer equation, Q0/Q and τ0/τ values are proportional to pO2, and our results
are similar to the report [31]. Therefore, phosphoresce intensity (Q) is inversely proportional
to pO2.
Cytotoxicity evaluation of BTP
To evaluate the cytotoxicity of BTP, we examined cell viability according to necrosis and apo-
ptosis in CT-26 cells using trypan blue dye-exclusion and Hoechst 33342 plus PI assays. Necro-
sis and apoptosis of cells treated with BTP were comparable with those observed in cells treated
with the cholesterol control (Fig. 2C). Treatment with BTP concentrations of less than 100 μM
yielded a cell necrosis rate of less than 10% and a cell apoptosis rate below 2%. In our previous
discussion, we postulated that any cytotoxicity observed might be attributed to the presence of
organic solvents (DMSO as the solvents of BTP) injected along with BTP. The water soluble
nanoparticles containing a BTP derivative was low cytotoxicity to avoid used organic solvent.
In fact, BTP does not have obvious cytotoxicity if solvent is used less than 2% in cell medium
(v/v), and may be used as a safe phosphorescence probe in vivo.
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Cell uptake of BTP
Tumor cell cultures were utilized to examine cell uptake of BTP. CT-26 cells were treated with
5 μM of BTP under 5% (hypoxic) or 20% (normal) O2 and cultured for 2 h. Results showed
that hypoxic CT-26 cells displayed higher phosphorescence signals than cells under normal
pO2 (Fig. 3).
Monitoring tumor hypoxic level changes in microenvironment in vivo and
the pathological and immunohistochemical studies
CT-26 tumor-bearing nude mice were treated with low-dose metronomic curing with cisplatin,
and BTP accumulation in the tumor site was observed using a Maestro 2 fluorescence imaging
system. Fig. 4A shows significant inhibition of tumor growth in cisplatin-treated mice
(p<0.01) compared with that in saline control mice; BTP signals significantly increased over
the treatment period (Day 18: p = 0.049; Day 21: p<0.01). This phenomenon indicates that cis-
platin inhibited tumor growth and increased tumor hypoxia. Using the same imaging
Fig 2. The physical and cytotoxicity properties of BTP. (A) The excitation and emission spectra of BTP; the emission spectra include two curves which
are at the air and nitrogen atmospheres, corresponding to two quartz cuvettes, respectively. (B) The relationship between the pO2 and phosphoresce
intensity. (C) Cytotoxicity evaluation of BTP: Trypan blue dye exclusion assay to measure the cell necrosis rate and Hoechst33342 plus PI assay to measure
the cell apoptosis rate (n = 10).
doi:10.1371/journal.pone.0121293.g002
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technique in vivo, a mouse treated with saline and another mouse treated with cisplatin were
observed continually from Days 9 to 21. Fig. 5 illustrates that the mouse in the saline group
showed gradual increases in tumor size as the phosphorescence intensity increased. By con-
trast, the mouse in the cisplatin group displayed a smaller tumor as well as a sharper increase
in phosphorescence intensity. Here, we defined phosphorescence intensity using a color bar:
long-wavelength colors present strong intensity while short wavelength colors mean weak in-
tensity. Images of the groups on Day 18 (when significant differences were first observed) are
shown in Fig. 6. While the tumor size in mice in the saline group was higher than that in mice
in the cisplatin group, the images did not show clear boundaries and the morphology of tumors
could not be examined completely. Besides the strong phosphorescence intensity of tumors in
mice in the cisplatin group, a high-contrast contour might also be observed, which indicated
that O2 distribution between tumors and normal tissues was quite different, especially under
chemotherapeutic conditions, when changes in the tumor microenvironment might occur.
Upon completion of tumor hypoxia imaging, the CT-26 tumor-bearing mice were sacri-
ficed. Tumors were harvested, sectioned, subjected to H&E staining, and then immunohisto-
chemically stained with HIF-1α or VEGF (Fig. 7). Pathological sections illustrate that tumor
cells died and tissues appeared empty under chemotherapy. The immunohistochemical stain
of HIF-1α shows that HIF-1α expression was higher in the cisplatin group (darker brown area,
Day 9: p = 0.013; Day 21: p = 0.487) than in the saline group, which indicated a positive rela-
tionship with hypoxic conditions. The immunohistochemical stain of VEGF shows that VEGF
expression was higher in the cisplatin group than in the saline group. However, it had no signif-
icant difference between two groups (Day 9: p = 0.339; Day 21: p = 0.128) for two reasons. One
was the suppression of cisplatin, and the other was induced expression by HIF-1. They made
VEGF neither increased nor decreased. Quantitative data of IOD SUM were extracted and
shown in Fig. 4C and 4D. HIF-1α expressed a trend similar to that of phosphorescence
Fig 3. The phosphorescence imaging in vitro. CT-26 cells uptake of BTP imaged using an inverted
fluorescence microscope as well as a camera, including blank control, BTP under 20%O2 (BTP normoxia)
and BTP under 5% O2 (BTP hypoxia). There are three columns including a bright field, a dark field and a
merged field. The first column presents the bright field under an inverted microscope; the second column
shows the phosphorescence images of cells as the bright field graphs without any moving, and the third one
merged them.
doi:10.1371/journal.pone.0121293.g003
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Fig 4. The phosphorescence imaging in vivo and immunohistochemical stain. (A) The growth curves of CT-26 xenografts after transplantation into
BALB/c nude mice treated with saline and cisplatin (n = 6). (B) The phosphorescence intensity of tumor imaging of CT-26 xenografts after transplantation into
BALB/c nude mice treated with saline and cisplatin (n = 6). (C) The quantitative data curves of immunohistochemical stain of HIF-1α in tumor-bearing mice
treated with saline and cisplatin, respectively (n = 3). (D) The quantitative data curves of immunohistochemical stain of VEGF in tumor-bearing mice treated
with saline and cisplatin, respectively (n = 3). Saline (100 μL) or cisplatin (1 mgkg-1, 100 μL).
doi:10.1371/journal.pone.0121293.g004
Fig 5. The BTP phosphorescence imaging for monitoring tumor hypoxic microenvironment in vivo at different time points (Days 9–21). The
cisplatin was used as an anti-tumor agent, and saline was injected as a contrast (n = 6). Scale bar = 10 mm.
doi:10.1371/journal.pone.0121293.g005
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intensity, which showed a linear relationship with O2 concentration (Stern-Volmer equation)
[32]. HIF-1α expression was always higher in the cisplatin group than that in the saline group.
As an up-regulated protein by hypoxia, VEGF expression gradually decreased in the cisplatin
group but initially increased and then decreased in the saline group (Fig. 4C and 4D).
Discussion
Commonly used measurement for tumor hypoxia includes HIF-1α immunohistochemistry as-
sessment, oxygen electrode probe, PET radiotracers such as 18F-FMISO, 18F-FAZA, Cu (II)-
ATSM. Oxygen electrode probe usually provides a minimum invasive measurement for the
local oxygen level and may vary largely by the detecting position. In contrast, PET hypoxia im-
aging can offer an alternative way with non-invasive, overall and accurate hypoxia imaging.
However, it may require the high cost facilities and has radiation exposure. In the current
study, we used HIF-1α immunohistochemistry staining to validate our findings of BTP-based
imaging. However, it is beyond the scope of the current study. Further study may involve a
Fig 6. The BTP phosphorescence imaging between cisplatin and saline groups for monitoring tumor hypoxic microenvironment in vivo on Day 18
(n = 6).Mice #1–6 are labeled in both cisplatin and saline treatment groups. Scale bar = 10 mm.
doi:10.1371/journal.pone.0121293.g006
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dual model imaging (BTP and PET hypoxia imaging) to validate the oxygen level in
tumor area.
To explain the various phenomena in our research, we focus on the HIF-1 cellular signal
pathway, which has been investigated for many years [2]. HIF-1 can activate transcription of
many genes involved angiogenesis, cell growth and survival, glucose metabolism, invasion, me-
tastasis, and drug resistance, among other [3]. HIF-1α protein expression is similar in nor-
moxic and hypoxic conditions but tends to stabilize in hypoxic environments. HIF-1α
combines with HIF-1β and activates several HIF-1 target gene to express proteins, such as
VEGF [33, 34], which is a significant protein involved in angiogenesis. Overexpression of
VEGF can contribute to so many diseases, especially solid-tumors. Tumors are unable to grow
beyond a limited size in the absence of adequate blood supply. HIF-1-mediated VEGF leads to
angiogenesis, resulting in remittance of hypoxic conditions and tumor metastasis. A rapid rate
of tumor growth makes the blood supply again become inadequate, the new circle will occur
and finally a balance will be achieved. In Fig. 8, hypoxia-influencing factors are illustrated in a
chain. Factors marked with “+” indicate a positive correlation, and factors marked with “-” in-
dicate a negative correlation. The hypoxic level kept spiraling, which was confirmed by BTP
phosphorescence in our research that was shown in Fig. 4B.
When tumors are treated by chemotherapy, the hypoxic condition is changed. Cisplatin, a
well-studied and commonly used anti-cancer chemotherapy drugs against different human tu-
mors, was used in the present work as a model drug. These series of non-target drugs react in
vivo, binding to and causing crosslinks of DNA, which ultimately trigger apoptosis. However,
previous reports have shown that various cytotoxic chemotherapeutic agents exert anti-angio-
genesis effects because the response of chemotherapeutic drugs to vascular endothelial cells
were 10–10,000 times more sensitive than that of tumor cells [10, 11]. Although cisplatin is not
a target drug of angiogenesis, low-dose metronomic treatment with cisplatin yields anti-angio-
genesis effects and restrains the expression of HIF-1α and VEGF [12, 13]. If these proteins are
restrained, the angiogenesis is suppressed, but the hypoxic condition may be intensified. In our
Fig 7. The H&E stain of pathological sections and immunohistochemical stain of mouse HIF-1α and
VEGF of tumor tissues onmice treated with saline and cisplatin.
doi:10.1371/journal.pone.0121293.g007
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studies, low-dose metronomic treatment with cisplatin caused anti-angiogenetic effects, and
less O2 could be delivered to tumors. Finally, BTP phosphorescence intensity increased but the
level of HIF-1α was influenced by both chemotherapy and pO2 in different directions, and its
expression would be relied on whose power was stronger.
Angiogenesisis one of the fastest growing fields in biomedical research, and advances in our
basic understanding of the process and its clinical application have been rapidly increased.
However, the effects of angiogenesis remain controversial. Angiogenesis is a complex, highly
orchestrated process that plays a critical role in the normal development and pathophysiology
of common diseases. The conventional rationale of anti-angiogenesis therapy is that suppres-
sion of angiogenesis and blood supply, which can cause tumor death through ‘‘starvation” [4].
However, the concept of ‘‘vascular normalization,” which was proposed by Jain et al. [8], pro-
vides another explanation for this phenomenon. Jain et al. hypothesized that anti-angiogenesis
actually ‘‘normalizes” the tumor vasculature, transiently increases blood perfusion within the
tumor, and alleviates hypoxia, thereby enhancing the delivery of oxygen and drugs to tumor
cells to increase the malignancies’ response to chemotherapy [35]. These phenotypic changes
in vasculature represent a response to changes in the balance of pro- and anti-angiogenesis fac-
tors in the tumor tissue [8].
In this current work, we made a proposal that three cases (Type I, II and III) were in the bal-
ance of pro- and anti-angiogenesis factors (Table 1). Type I: investigations of predecessors
showed that tumor cells become anoxic, inducing cell death [36]. In this case, the anti-angio-
genesis affects blood vessels inadequately, causing an increase in the phosphorescence intensity
with shortening tumor volumes. However, these anti-angiogenesis drugs are seldom available.
Type II: if the anti-angiogenesis effects are not enough, the cells under non-fatal hypoxia may
Fig 8. The HIF-1α/VEGF cellular signal pathway and their relationship to pO2 and BTP
phosphorescence.
doi:10.1371/journal.pone.0121293.g008
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increase the chemotherapy or radiotherapy resistance [37–39], and natural selections will
choose the cells with higher tolerance of hypoxia [40]. In this situation, the volume of tumors is
inhibited with a low growth speed but the phosphorescence intensity is increased. Type III: vas-
cular normalization has occurred, enhancing the delivery of oxygen and drugs to tumor cells
[8], and the phosphorescence intensity is down, but the tumors rapidly grow. Besides, we were
unable to find that the volume of tumors decreased with low phosphorescence intensity. We
predict it can be observed when tumors are cured.
According to the data of phosphorescence intensity, pO2 in tumors could be calculated
using the Stern-Volmer equation:
Q0
Q
¼ τ0
τ
¼ 1þ K½pO2 ¼ 1þ kqτ0½pO2 ð1Þ
where Q0, κq, and τ0 in tumor tissues were obtained from our current and previous work (Q0 =
7.611×109 photcm-2s-1, κq = 1.2×104 mmHgs-1, τ 0 = 9.05 μs) [26, 27]. The results are shown
in S1 Table. The measurable range is shown in Fig. 2B, in which 0–60 mmHg is suitable to be
measured with BTP; the relationship between three types in the balance of pro- and anti-angio-
genesis is summarized in Table 1. The distinguishing standard of three types (pO2 in tumors) is
set by our data, oxygen dissociation curve of capillary vessels [41], and reference [42].
Other groups showed different results with different dose of treatment, which were shown
in S1 Fig. This is the reason that the anti-VEGF agents were singly used, whose therapy effects
might be weak and disappointing. Targeting of hypoxia in cancer therapy must consider the
combination styles and doses of drugs. For example, chemotherapeutic drugs combined with
anti-VEGF inhibitors may cause serious hypoxic conditions in tumors and increase the expres-
sion of HIF-1, which induces genes involved in chemotherapy resistance [37–39]. Normaliza-
tion of the tumor vasculature may also occur since the tumor volume depends on the
cytotoxicity of chemotherapeutic drugs. In our study, BTP phosphorescence indicated that
low-dose metronomic therapy with cisplatin could adequately suppress angiogenesis, though
we did not combine it with VEGF targeting drugs, which belonged to Type II drug effects.
However, some cases in our investigation showed that different doses or combinations might
cause Type III phenotypic in S1 Fig., and Type I is seldom found because hypoxia-induced cell
death is difficult to achieve by chemotherapy or anti-VEGF therapy. For example, the new cis-
platin group was close to Type I in the beginning, but became Type II accompanied with thera-
py, as well as combination group, and the single anti-VEGF group might be in Type III. The
phosphorescent data obtained in this work provided quantitative information on processes as-
sociated with cancer therapy. In summary, our research proposes a new phosphorescence im-
aging technique for monitoring hypoxic microenvironment in tumors subjected to
chemotherapy. The results of our work can help evaluate therapeutic effects and present new
insights into cancer prognosis and treatment.
Table 1. Three types in the balance of pro- and anti-angiogenesis.
Volume of tumors a Phosphorescence intensity pO2[41–42]
Type I − or + Strong <10 mmHg
Type II + or++ Medium 10–40 mmHg
Type III +++ Low 40–60 mmHg
Normal tissues [26] None Low 40–60 mmHg
a
“
−
” presents a decrease in tumor size and “+” presents an increase in tumor sizes; more “+” marks indicate rapid growth.
doi:10.1371/journal.pone.0121293.t001
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Conclusions
A novel method has been developed for monitoring chemotherapy-related changes in tumor
hypoxic microenvironment using the hypoxia-sensing probe iridium (III) coordination com-
pound BTP. This probe provides a useful method for quantitative evaluation of changes in
tumor hypoxia during chemotherapy. The proposed method is a promising phosphorescence
imaging technique for evaluating anti-angiogenetic chemotherapeutic effects in vivo.
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